title: Antibodies in action: role of human opsonins in killing Salmonella enterica serovar Typhi.
abstract: Although vaccines have been available for over a century, a correlate of protection for typhoid fever has yet to be identified. Antibodies are produced in response to typhoid infection and vaccination and are generally used as the gold standard for determining vaccine immunogenicity, even though their role in clearance of Salmonella enterica serovar Typhi infections is poorly defined. Here, we describe the first functional characterization of S. Typhi-specific antibodies following vaccination with a new vaccine, M01ZH09 (Ty2 ΔaroC ΔssaV). We determined that postvaccination sera increased the uptake of wild-type S. Typhi by human macrophages up to 2.3-fold relative to prevaccination (day 0) or placebo samples. These results were recapitulated using immunoglobulins purified from postvaccination serum, demonstrating that antibodies were largely responsible for increases in uptake. Imaging verified that macrophages internalized 2- to 9.5-fold more S. Typhi when the bacteria were opsonized with postvaccination sera than when the bacteria were opsonized with day 0 or placebo sera. Once inside macrophages, the survival of S. Typhi was reduced as much as 50% when opsonized with postvaccination sera relative to day 0 or placebo serum samples. Lastly, bactericidal assays indicated that antibodies generated postvaccination were recognized by complement factors and assisted in killing S. Typhi: mean postvaccination bactericidal antibody titers were higher at all time points than placebo and day 0 titers. These data clearly demonstrate that there are at least two mechanisms by which antibodies facilitate killing of S. Typhi. Future work could lead to improved immunogenicity tests associated with vaccine efficacy and the identification of correlates of protection against typhoid fever.
authors.affiliation: University of Vermont College of Medicine, Department of Medicine, Vaccine Testing Center and Unit of Infectious Diseases, Burlington, VT 05405, USA. janet.lindow@uvm.edu
authors.forename: Janet C
authors.initials: JC
authors.lastname: Lindow
authors.forename: Kelly A
authors.initials: KA
authors.lastname: Fimlaid
authors.forename: Janice Y
authors.initials: JY
authors.lastname: Bunn
authors.forename: Beth D
authors.initials: BD
authors.lastname: Kirkpatrick
mesh_terms: D000328:Adult; D000907:Antibodies, Bacterial; D001770:Blood Bactericidal Activity; D006801:Humans; D008264:Macrophages / Q000276:immunology; D050296:Microbial Viability / Q000276:immunology*; D009895:Opsonin Proteins / Q000276:immunology*; D010587:Phagocytosis; D012485:Salmonella typhi / Q000276:immunology*; D014436:Typhoid-Paratyphoid Vaccines / Q000008:administration & dosage / Q000276:immunology*
chemical_list: D000907:Antibodies, Bacterial; D009895:Opsonin Proteins; D014436:Typhoid-Paratyphoid Vaccines; C503988:typhoid vaccine M01ZH09